Literature DB >> 9124867

Efficacy of continuous flucytosine infusion against Candida lusitaniae in experimental hematogenous murine candidiasis.

N C Karyotakis1, E J Anaissie.   

Abstract

Candida lusitaniae may cause life-threatening infections in the immunocompromised host and may be resistant to amphotericin B. Flucytosine (5-FC) is very active against C. lusitaniae isolates in vitro, while the in vivo response of murine infection to 5-FC is not as good. To evaluate the hypothesis that this discrepancy may be primarily due to the short half-life of 5-FC in mice, we compared the same total dosage of 75 mg of 5-FC per kg of body weight per day given by bolus injections or infused continuously via a subcutaneously implanted pump in immunosuppressed CF1 mice infected with C. lusitaniae. The fungal titers in the kidneys of mice treated with the continuous 5-FC infusion were significantly lower (P < or = 0.05) than those in the kidneys of mice that received bolus injections once or thrice daily. The antifungal activity of 5-FC against murine candidiasis is best evaluated when the drug is administered by continuous infusion.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9124867      PMCID: PMC163648     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

Review 1.  Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review.

Authors:  E Anaissie
Journal:  Clin Infect Dis       Date:  1992-03       Impact factor: 9.079

2.  Fungemia in the immunocompromised host. Changing patterns, antigenemia, high mortality.

Authors:  F Meunier-Carpentier; T E Kiehn; D Armstrong
Journal:  Am J Med       Date:  1981-09       Impact factor: 4.965

Review 3.  Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy.

Authors:  P Francis; T J Walsh
Journal:  Clin Infect Dis       Date:  1992-12       Impact factor: 9.079

4.  Correlation of in vitro susceptibility test results with in vivo response: flucytosine therapy in a systemic candidiasis model.

Authors:  R L Stiller; J E Bennett; H J Scholer; M Wall; A Polak; D A Stevens
Journal:  J Infect Dis       Date:  1983-06       Impact factor: 5.226

5.  Fluconazole susceptibility testing of Candida albicans: microtiter method that is independent of inoculum size, temperature, and time of reading.

Authors:  E Anaissie; V Paetznick; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

Review 6.  Emergence of a new opportunistic pathogen, Candida lusitaniae.

Authors:  R J Blinkhorn; D Adelstein; P J Spagnuolo
Journal:  J Clin Microbiol       Date:  1989-02       Impact factor: 5.948

  6 in total
  2 in total

1.  Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis.

Authors:  Patrick Schwarz; Françoise Dromer; Olivier Lortholary; Eric Dannaoui
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

2.  In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model.

Authors:  D Andes; M van Ogtrop
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.